One of chemotherapy’s oldest weapons, the fluoropyrimidine family that anchors first-line treatment for colorectal cancer, has just been handed a surprising new ally: a naturally occurring, non-toxic ribonucleotide that most cells carry in abundance. In a study published in Advanced Science, researchers report that cytidine monophosphate, or CMP, dramatically amplifies the ability of the drug floxuridine to trigger a potent innate immune alarm inside cancer cells — a cascade so strong that it drove interferon-β gene expression up more than 300-fold in colorectal cancer cells. When the team packaged the drug and the nucleotide together into tiny lipid nanoparticles, the combination suppressed tumor growth far better than either component alone and, when paired with an anti-PD-L1 antibody, completely eliminated tumors in every mouse tested.
The finding rests on a deceptively simple biological insight. Cancer cells are addicted to nucleotides, the raw material of DNA and RNA, and they ramp up ribonucleotide production by 6 to 11-fold compared with normal proliferating cells to fuel their relentless division, metastasis, and drug resistance. But this hyperactive metabolism creates a vulnerability: when the balance between ribonucleotides and deoxyribonucleotides is thrown off, mitochondria become stressed, and their DNA — normally sealed inside these energy-producing organelles — leaks into the cytosol. The innate immune sensor cGAS recognizes this misplaced DNA and activates the STING pathway, prompting the cancer cell to pump out type I interferons and recruit the immune system against itself.
Fluoropyrimidines already exploit this logic in part. As antimetabolites, they disrupt nucleotide synthesis, damage DNA, and can ignite cGAS–STING signaling. Yet their clinical power has long been blunted by two problems: they are metabolically unstable, and they must compete with the supraphysiological pools of endogenous nucleotides that cancer cells maintain. Despite decades of optimization — enzyme inhibitors, the prodrug capecitabine, the S-1 regimen, trifluridine-tipiracil — outcomes in advanced colorectal cancer, which kills roughly 700,000 people each year, remain stubbornly poor. The Nanjing University-led team hypothesized that rather than fighting the tumor’s nucleotide surplus, they could weaponize it.
Through systematic screening of nucleotide combinations with floxuridine, they discovered that pyrimidine ribonucleotides — especially CMP — transformed the drug’s activity. The synergy was strikingly specific: CMP alone did nothing, and it barely enhanced the widely used drug 5-fluorouracil or its metabolite fluorouridine. Only floxuridine and its active metabolite FdUMP, which feed directly into deoxyribonucleotide metabolism, responded. This selectivity traces to metabolic partitioning: 5-fluorouracil preferentially enters RNA metabolism, while floxuridine is channeled toward FdUMP, the molecule that covalently inhibits thymidylate synthase, the enzyme that makes the essential DNA building block TMP.
CRISPR–Cas9 library screening revealed exactly which enzymes were holding floxuridine back. Five pyrimidine metabolism genes — CMPK1, CMPK2, TYMP, UPP1, and UPP2 — emerged as the top hits that, when lost, made cells more sensitive to the drug. Analyzing over 4,700 patient samples from The Cancer Genome Atlas, the team showed that patients whose tumors expressed low levels of these five genes survived significantly longer, underscoring their clinical relevance. Remarkably, CMP and its intracellular metabolites, including uridine and 2′-deoxyuridine, were able to engage all five enzymes simultaneously, as demonstrated by drug affinity responsive target stability assays. No existing small-molecule inhibitor achieves this multi-target blockade, and developing one would be costly and unpredictable.
The metabolic consequences were dramatic. Liquid chromatography–tandem mass spectrometry showed that CMP boosted peak intracellular FdUMP levels nearly 500-fold and extended the metabolite’s half-life from 0.14 hours to 3.45 hours — a more than 20-fold increase in persistence. Cellular thermal shift assays confirmed that the accumulated FdUMP bound and stabilized thymidylate synthase more effectively, deepening the blockade of TMP synthesis. When the team supplemented cells with TMP itself, the synergy vanished entirely, proving the mechanism runs through thymineless death rather than direct interference with DNA replication. Purine nucleotides, by contrast, were cytotoxic at high concentrations and offered no benefit.
Depleted TMP synthesis triggered exactly the mitochondrial crisis the researchers predicted. Quantitative PCR along the mitochondrial genome revealed a position-dependent gradient of copy-number loss spreading from the replication origin — a molecular fingerprint of stalled replication forks. Damaged mitochondrial DNA then escaped into the cytosol, largely through VDAC1 channels: blocking VDAC1 oligomerization with the inhibitor VBIT-4 suppressed the interferon response just as effectively as depleting mitochondrial DNA altogether. Pharmacological inhibition of cGAS with RU.521 or of STING with H-151 likewise shut down the signal, and tumors grew poorly in response to the combination only in mice with functional STING.
Translating the chemistry into a clinic-ready formulation required solving a delivery dilemma. CMP and FdUMP are both highly hydrophilic, poorly permeable molecules, and the synergy collapsed when dosing intervals exceeded two hours — evidence that the two must be metabolized inside the same cell at the same time. The team exploited metal coordination chemistry, discovering that ferric iron could bridge the phosphate groups of CMP and FdUMP into self-assembling nanoscale coordination polymers. Wrapped in a PEGylated lipid shell, the resulting FC-NPs measured roughly 107 nanometers, remained stable in the bloodstream, and released their payload only in the acidic environment of endosomes, achieving true synchronized co-delivery.
In mouse models of colorectal cancer, the nanoparticles delivered on their promise. Three intratumoral injections of FC-NPs inhibited MC38 tumor growth by 82 percent, compared with just 31 percent for the free drug mixture, while cutting the required dosing frequency from thrice daily to once daily. Treated tumors flooded with IFN-β, CXCL10, TNF-α, and IFN-γ, and produced markedly more tumor antigen-specific CD8-positive T cells. The efficacy vanished in mice lacking cross-presenting dendritic cells or depleted of CD8-positive T cells, confirming that adaptive antitumor immunity — the downstream product of STING activation — was the engine of the response. Most strikingly, adding anti-PD-L1 antibody to the nanoparticles produced complete tumor rejection in all treated mice, a result neither therapy achieved alone. Because floxuridine is already the standard agent for hepatic artery infusion in colorectal liver metastases, the authors argue that co-delivering CMP in that regional setting offers a direct, actionable path to the clinic, with CMP showing good biosafety in vivo.
Subject of Research: A metabolic strategy in which ribonucleotides amplify fluoropyrimidine-induced mitochondrial DNA release and cGAS–STING activation to potentiate colorectal cancer chemoimmunotherapy
Article Title: Ribonucleotides Amplify Mitochondrial DNA‐Driven cGAS–STING Activation via FdUMP‐ribonucleotide Hybrid Particles to Potentiate Chemoimmunotherapy
Article References: Wang, C., Zhao, C., Yao, Y., Zou, Z., Shi, A., Feng, Z., Yang, M., Yu, Y., Liu, Y., Rui, X., & Wu, J. (2026). Ribonucleotides Amplify Mitochondrial DNA‐Driven cGAS–STING Activation via FdUMP‐ribonucleotide Hybrid Particles to Potentiate Chemoimmunotherapy. Advanced Science, Article e77614. https://doi.org/10.1002/advs.77614
Image Credits: AI Generated
DOI: 10.1002/advs.77614
Keywords: cGAS–STING, mitochondrial DNA, ribonucleotides, floxuridine, colorectal cancer, chemoimmunotherapy, lipid nanoparticles, nucleotide metabolism, FdUMP, thymidylate synthase, PD-L1 blockade, CRISPR screen
Cite Scienmag News
APA MLA Chicago
Nathaniel Bowman. (September 23, 2026). Ribonucleotides Supercharge Cancer Chemotherapy Through Mitochondrial DNA Stress. Scienmag. https://scienmag.com/ribonucleotides-supercharge-cancer-chemotherapy-through-mitochondrial-dna-stress/
Nathaniel Bowman. “Ribonucleotides Supercharge Cancer Chemotherapy Through Mitochondrial DNA Stress.” Scienmag, 23 September 2026, https://scienmag.com/ribonucleotides-supercharge-cancer-chemotherapy-through-mitochondrial-dna-stress/. Accessed 23 September 2026.
Nathaniel Bowman. “Ribonucleotides Supercharge Cancer Chemotherapy Through Mitochondrial DNA Stress.” Scienmag. September 23, 2026. https://scienmag.com/ribonucleotides-supercharge-cancer-chemotherapy-through-mitochondrial-dna-stress/
Copy citation Download RIS
Tags: cancer chemotherapy enhancementcGAS-STINGchemoimmunotherapyColorectal cancercolorectal cancer treatment strategiescombination immunotherapy with anti-PD-L1CRISPR screencytidine monophosphate in tumor therapyFdUMPfloxuridinefluoropyrimidine drug mechanisminnate immune response in cancer cellslipid nanoparticle drug deliverylipid nanoparticlesmitochondrial DNAmitochondrial DNA stress in cancermitochondrial stress-induced tumor suppressionnucleotide metabolismnucleotide metabolism in cancer cellsPD-L1 blockaderibonucleotidesribonucleotides in cancer treatmentrole of ribonucleotides in enhancing chemotherapythymidylate synthase
